FDMT Key Statistics, Chart & Performance
The current stock price of FDMT is 7.58 USD. In the past month the price decreased by -27.88%. In the past year, price increased by 27.82%.
FDMT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.31 | 406.04B | ||
| AMGN | AMGEN INC | 15.03 | 176.99B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.14 | 115.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.92 | 52.48B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 31.74B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.8 | 21.37B | ||
| INCY | INCYTE CORP | 15.41 | 19.42B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About FDMT
Company Profile
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. The company is headquartered in Emeryville, California and currently employs 227 full-time employees. The company went IPO on 2020-12-11. The firm's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The firm is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The firm's non-core programs include 4D-175, 4D-725, and 4D-310.
Company Info
4D MOLECULAR THERAPEUTICS IN
5858 Horton Street #455, Emeryville
Emeryville CALIFORNIA US
Employees: 227
Phone: 15105052680
4D MOLECULAR THERAPEUTICS IN / FDMT FAQ
What does FDMT do?
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. The company is headquartered in Emeryville, California and currently employs 227 full-time employees. The company went IPO on 2020-12-11. The firm's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The firm is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The firm's non-core programs include 4D-175, 4D-725, and 4D-310.
Can you provide the latest stock price for 4D MOLECULAR THERAPEUTICS IN?
The current stock price of FDMT is 7.58 USD. The price decreased by -1.3% in the last trading session.
Does 4D MOLECULAR THERAPEUTICS IN pay dividends?
FDMT does not pay a dividend.
What is the ChartMill rating of 4D MOLECULAR THERAPEUTICS IN stock?
FDMT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for FDMT stock?
4D MOLECULAR THERAPEUTICS IN (FDMT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.75).
Can you provide the market cap for 4D MOLECULAR THERAPEUTICS IN?
4D MOLECULAR THERAPEUTICS IN (FDMT) has a market capitalization of 433.12M USD. This makes FDMT a Small Cap stock.
Can you provide the short interest for FDMT stock?
The outstanding short interest for 4D MOLECULAR THERAPEUTICS IN (FDMT) is 9.09% of its float.
FDMT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FDMT. When comparing the yearly performance of all stocks, FDMT turns out to be only a medium performer in the overall market: it outperformed 68.95% of all stocks.
FDMT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FDMT. While FDMT has a great health rating, there are worries on its profitability.
FDMT Financial Highlights
Over the last trailing twelve months FDMT reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS decreased by -32.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.34% | ||
| ROE | -56.69% | ||
| Debt/Equity | 0 |
FDMT Forecast & Estimates
17 analysts have analysed FDMT and the average price target is 33.77 USD. This implies a price increase of 345.56% is expected in the next year compared to the current price of 7.58.
For the next year, analysts expect an EPS growth of -25.86% and a revenue growth 404.1% for FDMT